difference between compound semaglutide and tirzepatide Compounded Injections $100 Compounded Semaglutide vs. Compounded Tirzepatide

Retatrutide is an investigational triple agonist activating GLP-1, GIP, and glucagon receptors simultaneously, producing greater weight reduction than single or dual agonists

Retatrutide is currently under investigation in a global phase 3 clinical trial programme, following promising results from its phase 2 study (NCT04881760) published in the New England Journal of Medicine in 2023

Mirabegron, a Selective 3-Adrenergic Receptor Agonist, as a Potential Anti-Obesity Drug

This program is designed to offer medically supervised weight loss through personalized guidance and support, ensuring that you receive the tools and knowledge to achieve sustainable results